Probiotics: A New Approach for the Prevention and Treatment of Cervical Cancer
- PMID: 39951049
- DOI: 10.1007/s12602-025-10479-5
Probiotics: A New Approach for the Prevention and Treatment of Cervical Cancer
Abstract
Cervical cancer is closely linked to high-risk human papillomavirus (HR-HPV) infections which could crosstalk with the diversity of microorganisms within the cervicovaginal microbiota (CVM). Conventional treatments can disrupt the host microbial communities, which in turn affect the efficacy and side effects of these interventions, potentially jeopardizing the lives and health of patients. Therefore, there is a need to develop new approaches for the prevention and treatment of cervical cancer, and probiotics have shown significant potential as effective agents against cervical cancer. Studies have demonstrated that probiotics induce anticancer action by inducing apoptosis in tumor cells, inhibiting metastasis, reducing inflammation, enhancing immune functions, and modifying the effect of chemo/radiation therapy. Recent reports showed that probiotics had the ability to restore the CVM, clear HPV infections in cervical epithelial cells, and modulate immune responses. Despite these promising findings, the efficacy and safety of probiotic formulations require further validation through comprehensive research. This review focused on elucidating the mechanism behind the anticancer action and the importance of addressing the challenges associated with the clinical application of probiotics to realize their full potential as a novel and complementary approach in the prevention and treatment of cervical cancer.
Keywords: Anticancer therapy; Cervical cancer; Cervicovaginal microbiota; Gut microbiota; Probiotics.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of Interest: The authors declare no competing interests.
Similar articles
-
Cervicovaginal microbiome, high-risk HPV infection and cervical cancer: Mechanisms and therapeutic potential.Microbiol Res. 2024 Oct;287:127857. doi: 10.1016/j.micres.2024.127857. Epub 2024 Jul 26. Microbiol Res. 2024. PMID: 39121703 Review.
-
Application of probiotics in cervical cancer infections to enhance the immune response.Microb Pathog. 2024 Aug;193:106764. doi: 10.1016/j.micpath.2024.106764. Epub 2024 Jun 27. Microb Pathog. 2024. PMID: 38944216 Review.
-
Cervicovaginal microbiota: a promising direction for prevention and treatment in cervical cancer.Infect Agent Cancer. 2024 Apr 19;19(1):13. doi: 10.1186/s13027-024-00573-8. Infect Agent Cancer. 2024. PMID: 38641803 Free PMC article. Review.
-
Relationship between Human Papillomavirus Status and the Cervicovaginal Microbiome in Cervical Cancer.Microorganisms. 2023 May 27;11(6):1417. doi: 10.3390/microorganisms11061417. Microorganisms. 2023. PMID: 37374919 Free PMC article. Review.
-
The Interplay Between Cervicovaginal Microbiota Diversity, Lactobacillus Profiles and Human Papillomavirus in Cervical Cancer: A Systematic Review.Healthcare (Basel). 2025 Mar 10;13(6):599. doi: 10.3390/healthcare13060599. Healthcare (Basel). 2025. PMID: 40150449 Free PMC article. Review.
Cited by
-
Role of gut microbiome in suppression of cancers.Gut Microbes. 2025 Dec;17(1):2495183. doi: 10.1080/19490976.2025.2495183. Epub 2025 Apr 20. Gut Microbes. 2025. PMID: 40254597 Free PMC article. Review.
References
-
- Wen Y, Liang H, Zhang H (2023) Clinical utility of HPV typing and quantification combined with pax1/znf582 methylation detection in accurate cervical cancer screening. Cytojournal, 20: 26. https://doi.org/10.25259/Cytojournal_46_2022
-
- Utada M, Chernyavskiy P, Lee WJ, Franceschi S, Sauvaget C, De Gonzalez AB, Withrow DR (2019) Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer 144(9):2144–2152. https://doi.org/10.1002/ijc.32014 - DOI - PubMed
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.21834 - DOI - PubMed
-
- Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt BE, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, Mcmillian NR, Aggarwal S, Espinosa S (2023) Nccn guidelines® insights: cervical cancer, version 1.2024. J Natl Compr Canc Netw. 21(12):1224–1233. https://doi.org/10.6004/jnccn.2023.0062
-
- Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW (2022) He J (2024) [Cancer incidence and mortality in china. Zhonghua Zhong Liu Za Zhi 46(3):221–231. https://doi.org/10.3760/cma.j.cn112152-20240119-00035 - DOI
Publication types
Grants and funding
- A22-2-054/Yichang Medical and Health Research Project
- A24-2-058/Yichang Medical and Health Research Project
- 2022EGC-10/Open Foundation of Hubei Provincial Clinical Research Center for Precise Prevention and Treatment of Elderly Gastrointestinal Cancer
- 2023KZL028/Hubei Key Laboratory of Tumor Microenvironment and immunotherapy , China Three Gorges University
- NPRD 2018012/Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University
LinkOut - more resources
Full Text Sources